57 related articles for article (PubMed ID: 6305169)
21. Isoflavone genistein inhibits the angiotensin-converting enzyme and alters the vascular responses to angiotensin I and bradykinin.
Montenegro MF; Pessa LR; Tanus-Santos JE
Eur J Pharmacol; 2009 Apr; 607(1-3):173-7. PubMed ID: 19233159
[TBL] [Abstract][Full Text] [Related]
22. [The antifibrinolytic action of the D-dimer fragment].
Rozenfel'd MA; Khavkina LS; Leonova VB; Gershkovich KB; Vasil'eva MV
Izv Akad Nauk SSSR Biol; 1989; (6):855-61. PubMed ID: 2621282
[TBL] [Abstract][Full Text] [Related]
23. Inhibition of angiotensin converting enzyme of rat brain with bradykinin and its fragments.
Kariya K; Okamoto H; Kakimoto M; Tsuda Y; Okada Y
Biochem Biophys Res Commun; 1981 May; 100(1):31-6. PubMed ID: 6266403
[No Abstract] [Full Text] [Related]
24. Effect of a fibrin-derived vasoactive peptide on pulmonary angiotensin converting enzyme activity and on pressure responses to bradykinin.
Moalli R; Saldeen K; Saldeen T
J Pharmacol Exp Ther; 1987 Dec; 243(3):897-900. PubMed ID: 3694536
[TBL] [Abstract][Full Text] [Related]
25. Structure-activity relationships in bradykinin analogues.
Stewart JM
Fed Proc; 1968; 27(1):63-6. PubMed ID: 4952634
[No Abstract] [Full Text] [Related]
26. Bradykinin derivatives as permeability factors.
Reis ML; Okino L; Rocha e Silva M
Agents Actions; 1973 Dec; 3(5):383. PubMed ID: 4785039
[No Abstract] [Full Text] [Related]
27. Bradykinin analogs as inhibitors of angiotensin-converting enzyme.
Chaturvedi D; Huelar E; Gunthorpe M; Gofman M; Krapf DS; Apostol E; Lewis WS
Pept Res; 1993; 6(6):308-12. PubMed ID: 8292848
[TBL] [Abstract][Full Text] [Related]
28. [Potentiative effects of angiotensin converting enzyme inhibitors on carrageenan-induced edema in rats].
Suda H; Yamauchi H; Iso T
Nihon Yakurigaku Zasshi; 1982 Dec; 80(6):517-23. PubMed ID: 6298082
[TBL] [Abstract][Full Text] [Related]
29. Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
Gonzalez Vera W; Fournié-Zaluski MC; Pham I; Laboulandine I; Roques BP; Michel JB
J Pharmacol Exp Ther; 1995 Jan; 272(1):343-51. PubMed ID: 7815350
[TBL] [Abstract][Full Text] [Related]
30. [Inhibition of fibrin monomer polymerization by fibrinolysis products--fragments D and DD].
Belitser VA; Platonova TN; Musialkovskaia AA
Dokl Akad Nauk SSSR; 1986; 291(4):1001-4. PubMed ID: 3803182
[No Abstract] [Full Text] [Related]
31. Flaujeac factor deficiency. Reconstitution with highly purified bovine high molecular weight-kininogen and delineation of a new permeability-enhancing peptide released by plasma kallikrein from bovine high molecular weight-kininogen.
Matheson RT; Miller DR; Lacombe MJ; Han YN; Iwanaga S; Kato H; wuepper KD
J Clin Invest; 1976 Dec; 58(6):1395-406. PubMed ID: 993350
[TBL] [Abstract][Full Text] [Related]
32. [The effect of bradykinin and histamine on capillary permeability].
Gaponiuk PIa; Oĭvin VI
Biull Eksp Biol Med; 1968 May; 65(5):31-4. PubMed ID: 5757798
[No Abstract] [Full Text] [Related]
33. Bradykinin-induced airway microvascular leakage and bronchoconstriction are mediated via a bradykinin B2 receptor.
Farmer SG
Am Rev Respir Dis; 1991 Jul; 144(1):237-9. PubMed ID: 1648315
[No Abstract] [Full Text] [Related]
34. Selective angiotensin-converting enzyme C-domain inhibition is sufficient to prevent angiotensin I-induced vasoconstriction.
van Esch JH; Tom B; Dive V; Batenburg WW; Georgiadis D; Yiotakis A; van Gool JM; de Bruijn RJ; de Vries R; Danser AH
Hypertension; 2005 Jan; 45(1):120-5. PubMed ID: 15583077
[TBL] [Abstract][Full Text] [Related]
35. Metabolism of bradykinin by peptidases in the lung.
Dragović T; Igić R; Erdös EG; Rabito SF
Am Rev Respir Dis; 1993 Jun; 147(6 Pt 1):1491-6. PubMed ID: 8389109
[TBL] [Abstract][Full Text] [Related]
36. Effects of converting-enzyme inhibitors on the renin-angiotensin-aldosterone, bradykinin, and arachidonic acid-prostaglandin systems: correlation of chemical structure and biologic activity.
Zusman RM
Am J Kidney Dis; 1987 Jul; 10(1 Suppl 1):13-23. PubMed ID: 3037886
[TBL] [Abstract][Full Text] [Related]
37. Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes.
Gilbert RE; Kelly DJ; Cox AJ; Wilkinson-Berka JL; Rumble JR; Osicka T; Panagiotopoulos S; Lee V; Hendrich EC; Jerums G; Cooper ME
Diabetologia; 2000 Nov; 43(11):1360-7. PubMed ID: 11126403
[TBL] [Abstract][Full Text] [Related]
38. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
Cruden NL; Fox KA; Ludlam CA; Johnston NR; Newby DE
Hypertension; 2004 Dec; 44(6):913-8. PubMed ID: 15492133
[TBL] [Abstract][Full Text] [Related]
39. Inhibitors of the pulmonary angiotensin I-converting enzyme.
Sander GE; West DW; Huggins CG
Biochim Biophys Acta; 1972 Dec; 289(2):392-400. PubMed ID: 4346517
[No Abstract] [Full Text] [Related]
40. Circular dichroism spectra of some lower homologs of bradykinin potentiating peptide 9 alpha.
Marlborough DI; Fisher GH; Ryan JW
Arch Biochem Biophys; 1981 Aug; 210(1):43-8. PubMed ID: 6271072
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
